Fri, Jul 25, 2014, 3:50 AM EDT - U.S. Markets open in 5 hrs 40 mins

Recent

% | $
Click the to save as a favorite.

Abbott Laboratories Message Board

  • cli2 cli2 May 13, 1998 10:14 AM Flag

    Look for a gap up in the next two weeks

    There should be some buying in the next two weeks
    in conjuction with the split. The company will most
    likely do the buying--part of the share buy back plan to
    boost the price prior to the split. we might see 75-78
    range again. I seriously doubt it will go up to 80.
    Watch it out.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • I agree with you on the price range. I think the
      creeping is underway. I also believe by the 28th it will
      hit 78-79 area. Now the Post Price should be 40-42.
      My reasoning is they did increase the div. Also when
      an issue goes When Issue(WI) it usually trades a
      half to one & one half points higher. This seems to be
      the case of most of the stocks splits that I've been
      part of.

      I know there are complants about the
      pipeline of new products.
      ABT web site is not a good
      one for investor information. I wonder if investors
      online complain via their E-Mail at the site.
      Intel's
      site is an excellent site for information. Just a
      thought.

      • 1 Reply to surenotsure
      • I also agree with the analysis. The reason given
        by cli2 is sound. I used to work at Abbott, although
        the pipeline in pharmaceutical area is weak, its
        diagnostic division is fairly strong and is picking up
        stength and it will carry Abbott for the next few
        quarters. I actually think Abbott will be doing slightly
        better than most analysts predicted. The management
        changes are definitely good for Abbott, and will carry it
        to the 21st century. Look for a number of potential
        acquisitions Abbott will engage in the next several months,
        including top biotech companies, generic drug companies
        (!!!!) and genomic firms. At least we will see one such
        merger or buyout this year--it is an easy prediction
        because that is what Abbott has to do and must do.
        Potential targets are Eli Lilly, Pathogenesis, Andrex,
        Curagen and Aurora Bioscience, etc. Got to go, good luck
        and be patient.

 
ABT
42.89-0.08(-0.19%)Jul 24 4:02 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.